Abstract:Inactivation of p53 is present in almost every tumor, and hence, p53-reactivation strategies are an important aspect of cancer therapy. Common mechanisms for p53 loss in cancer include expression of p53-negative regulators such as MDM2, which mediate the degradation of wildtype p53 (p53α), and inactivating mutations in the TP53 gene. Currently, approaches to overcome p53 deficiency in these cancers are limited. Here, using non-small cell lung cancer and glioblastoma multiforme cell line models, we show that two alternatively spliced, functional truncated isoforms of p53 (p53β and p53γ, comprising exons 1 to 9β or 9γ, respectively) and that lack the C-terminal MDM2-binding domain have markedly reduced susceptibility to MDM2-mediated degradation but are highly susceptible to nonsense-mediated decay (NMD), a regulator of aberrant mRNA stability. In cancer cells harboring MDM2 overexpression or TP53 mutations downstream of exon 9, NMD inhibition markedly upregulates p53β and p53γ and restores activation of the p53 pathway. Consistent with p53 pathway activation, NMD inhibition induces tumor suppressive activities such as apoptosis, reduced cell viability, and enhanced tumor radiosensitivity, in a relatively p53-dependent manner. In addition, NMD inhibition also inhibits tumor growth in a MDM2-overexpressing xenograft tumor model. These results identify NMD inhibition as a novel therapeutic strategy for restoration of p53 function in p53-deficient tumors bearing MDM2 overexpression or p53 mutations downstream of exon 9, subgroups that comprise approximately 6% of all cancers.

The Regulation of MDM2 Oncogene and Its Impact on Human Cancers

Targeting Mouse Double Minute 2: Current Concepts in DNA Damage Repair and Therapeutic Approaches in Cancer.

MDM2: current research status and prospects of tumor treatment

Inhibition of Nonsense-Mediated Decay Rescues P53β/γ Isoform Expression and Activates the P53 Pathway in MDM2-overexpressing and Select P53-Mutant Cancers

The Regulation of the P53/mdm2 Feedback Loop by Micrornas.

Small Molecule Inhibitors of the P53-Mdm2

Escape, or Vanish: Control the Fate of p53 through MDM2-Mediated Ubiquitination.

MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy.

Regulation of MDM2 Stability After DNA Damage

Small Molecule Agents Targeting the P53-Mdm2 Pathway for Cancer Therapy

Complex Structures of Human MDM2 with Interacting Proteins Reveal the Regulation Mechanism of P53

Microrna-1827 Represses MDM2 to Positively Regulate Tumor Suppressor P53 and Suppress Tumorigenesis

Mdm2 links genotoxic stress and metabolism to p53

Research progress of regulation mechanism of MDMX and CK1αin p53 tumor suppressor protein

Mdm2 is A Negative Regulator of P21(Waf1/Cip1), Independent of P53

Targeting MDM2 for novel molecular therapy: Beyond oncology

Characterization of cancer-associated missense mutations in MDM2

MDM2 inhibitors in cancer immunotherapy: Current status and perspective

Novel MDM2 p53-independent functions identified through RNA silencing technologies.

Advances in Study of Murine Double Minute 2/p53 Passway with Breast Cancer

Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials